Events

Want to know which industry events we are participating in and where you can meet some of the Celixir team? Check out our calendar below which gives a list of upcoming and previous events from all over the globe.

Upcoming Events
22
Aug
2018
Whether you attended an Executive Education program at Harvard Business School last year or 10 years ago, the business world and the HBS campus continues...
11
Sep
2018
Please see http://www.phacilitate-leaders-europe.com/ for more information.
26
Sep
2018
Creating an interactive environment where business leaders can share the latest innovation and discuss relevant industry challenges, Proventa International has been connecting large to emerging...
3
Oct
2018
The Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the industry with the scientific...
3
Oct
2018
CBI’s Advanced Therapies Commercialisation Congress is a collaborative, multi-stakeholder meeting for exchanging views and exploring business approaches for the evolving ATMP segment. This congress convenes industry executives,...
17
Oct
2018
Please see https://www.biodeutschland.org/de/european-business-development-conference-2018.html for more information
29
Oct
2018
Please see https://www.terrapinn.com/conference/world-immunotherapy-congress/index.stm for more information.
4
Dec
2018
Please see https://www.biofit-event.com/ for more information.
Past Events
13
Aug
2018
ConferenceSeries Ltd invites all the participants from all over the world to attend "10th Annual Conference on Stem Cell and Regenerative Medicine" during August 13-14, 2018 at London, UK which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. Stem cells are cells originate in all multi-cellular organisms. They were isolated in mice in 1981 and in humans in 1998. In humans, there are several types of stem cells, each with varying levels of potency. Stem cell treatments are a type of cell therapy that introduces new cells into adult bodies for possible treatment of cancer, diabetes, neurological disorders and other medical conditions. Stem cells have been used to repair tissue damaged by disease or age. Currently, it has emerged as a rapidly diversifying field with the potential to address the worldwide organ shortage issue and comprises of tissue regeneration and organ replacement. The global tissue engineering and regeneration market reached $17 billion in 2013. This market is expected to grow to nearly $20.8 billion in 2014 and $56.9 billion in 2019, a compound annual growth rate (CAGR) of 22.3%. On the basis of geography, Europe holds the second place in the global market in the field of regenerative medicine & tissue engineering. In Europe countries like the UK, France and Germany are possessing good market shares in the field of regenerative medicine and tissue engineering. Spain and Italy are the emerging market trends for tissue engineering in Europe.
10
Jul
2018

The National Medtech & Biotech Summit is being held in the Arena MK, Milton Keynes on July 10th 2018.

This gathering of over 1000 senior management people from the Medtech and Biotech sectors, offers an opportunity for the sector to gather and keep up-to-date with the latest innovations, best practices and new technology solutions. Over 30 speakers and 50 exhibitors will both inform and educate the delegates who will network and listen to key note talks.
24
May
2018

Alternative Investment Forum is an invite-only, two-day event in Vilnius, Lithuania for Professional Investors, HNWI, Family Offices, Leading Entrepreneurs and CEO's.

DAY ONE

First day is dedicated to traditional alternative investments like Venture Capital, Hedge Funds, Real Estate.

DAY TWO

Second day is focused on Blockchain technology, cryptocurrency and ICO's

17
May
2018

In May 2018 the World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products). From clinical translation to commercialisation this congress will bring you the most exciting case studies and new data for stem cells, gene therapy, TCRs and gene editing. Experts in every area will help you tackle the process and regulatory hurdles of developing all new therapeutic formats all the way through manufacture and into the clinic.

The event will take place alongside the co-located World Precision Medicine Congress and Cord Blood World Europe, hosting 200+ speakers, 7 tracks of content across the 3 days, enabling networking opportunities with 800+ leading industry professionals.

Key topics include: The next generation of ATMPs Regulation, reimbursement & commercialisation for advanced therapies around the globe CRISPR & gene editing Stem cells as a tool for drug discovery What’s next for cell and gene therapy, new era of regenerative medicine? New paradigms in manufacture: gene therapy & viral vectors Clinical development of immunotherapy & cell therapy New frontiers in repair and replacement of diseased tissues & organs Product, process & manufacturing development of ATMPS
17
Apr
2018

The Alliance for Regenerative Medicine Releases Complete Agenda for Sixth Annual Cell & Gene Therapy Investor Day

WASHINGTON, DC, March 28, 2018 – The Alliance for Regenerative Medicine (ARM) today released the complete agenda for its upcoming sixth annual Cell & Gene Therapy Investor Day, taking place April 17, 2018 in New York City, NY. This event, co-hosted by Chardan, PNC Healthcare, Raymond James, and Solebury Trout, provides institutional, strategic, and venture investors with unique insight into financing opportunities for cell and gene therapy-based treatment and tools. This year’s Cell & Gene Therapy Investor Day is expected to attract more than 350 attendees, including nearly 200 active investors and analysts. With presentations from more than 35 of the sector’s most promising companies, along with panels and fireside chats by the field’s foremost thought leaders, this one-day meeting explores how cell and gene therapies are impacting key therapeutic areas, including oncology, ophthalmology, rare disease, diabetes, cardiovascular disease, wound healing and tissue repair, and neurodegenerative diseases.

2018 Panel Sessions and Speakers:

Featured Fireside Chat
  • Gbola Amusa, M.D., Partner, Director of Research and Head of Healthcare Research, Chardan (moderator)
  • Katherine High, M.D., President and Head of Research and Development, Spark Therapeutics
Panel I: Technology Trends: Leading Platforms Across the Cell and Gene Sector
  • Amy DuRoss, CEO, Vineti (moderator)
  • James Noble, CEO, Adaptimmune
  • Bob Smith, SVP, Global Gene Therapy Business, Pfizer
Panel II: The Immuno-Oncology Pipeline for Liquid and Solid Tumors
  • Robert Preti, Ph.D., President and CEO, Hitachi Chemical Advanced Therapeutics Solutions; GM, Hitachi Chemical Regenerative Medicine Business Sector (moderator)
  • Samuele Butera, Global Cell and Gene Therapies Business Leader, Novartis Oncology
  • Jennifer Butler, Chief Commercial Officer and Head of US, Tessa Therapeutics
  • Derrell Porter, M.D., SVP and Global Commercial Head, Atara Biotherapeutics
  • Jeffrey Walsh, Chief Financial and Strategy Officer, bluebird bio
Panel III: Gene Therapy for Rare Diseases
  • Ren Benjamin, Ph.D., SVP and Senior Biotechnology Analyst, Raymond James (moderator)
  • Timothy Miller, Ph.D., President and CEO, Abeona Therapeutics
  • Matt Patterson, CEO, Audentes Therapeutics
  • Arthur Tzianabos, Ph.D., CEO, Homology Medicines

2018 Presenting Companies:

4D Molecular Therapeutics; Adaptimmune; Adverum Biotechnologies; AGTC; Avery Therapeutics; BioCardia; bluebird bio; B-MoGen Biotechnologies; Brainstorm Cell Therapeutics; Capricor Therapeutics; Celixir; Cellerant Therapeutics; Cynata Therapeutics; Fibrocell; Frequency Therapeutics; Histogen; Histogenics; inRegen; Iovance Biotherapeutics; Kiadis Pharma; LogicBio; Mesoblast; Miromatrix; MolMed S.p.A.; Neuralstem; Orchard Therapeutics; Oxford BioMedica; Precision BioSciences; Regenerex; ReNeuron; Sernova Corp.; Synpromics; Thrive Bioscience; Tmunity; Vericel; and ViaCyte.  Full agenda and details available at www.arminvestorday.com. Sponsors for this year’s event include Cognate BioServices; Cryoport; Crossover Search; CTI Clinical Trial & Consulting; Defined Health; Kawasaki; KBI Biopharma; Lonza; Medpace; and PCT, a Hitachi Group Company. Marketing partners include Antenna Group and Edison. The event will be held April 17, 2018, beginning at 7:30am at The Metropolitan Club, One East 60th Street, New York, NY 10022.

About The Alliance for Regenerative Medicine:

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 290 members and is the leading global advocacy organization in this field.    
14
Mar
2018
The Advanced Therapies Summit is a gathering of top executives and policy makers leading the evolution of the ATMP framework in Europe and key member states. This year’s program will feature roundtable discussions and networking opportunities. The Advanced Therapies Summit is a multi-stakeholder, interactive forum that seeks to exchange views and make recommendations on how best to advance the ATMP sector in Europe. The conference brings together the top executives, public policy makers and other members of the advanced therapies community to highlight the major achievements and explore the main challenges experienced along the path from discovery to delivery of transformative – and even potentially curative – therapies. This year’s program will feature interactive discussions and networking opportunities with policy makers leading the evolution of the ATMP framework in Europe and executives from leading companies in the ATMP sector.
16
Nov
2017
Organized by World High Technology Society (WHTS), The 11th Annual World Congress of Regenerative Medicine & Stem Cell-2017 was held successfully at Holiday Inn Singapore Atrium during November 14-16, 2017. Read more about the event here.
10
May
2017
“The differences in culture of institutional biotech investors in Europe versus the US, and how that impacts the ability of individual biotechs to grow and commercialise.”
17
Apr
2017
“Introduction to cell & gene therapy” and “Topic Based Partnering” Event details here
Twitter Feed